Sophia Genetics
The firm may draw additional revenues later this year from a forthcoming clinical decision support product.
Sophia Genetics Q1 Revenues Increase 21 Percent
The company "remains comfortable" with the low end of its previous revenue guidance for 2022 of $51.5 million to $54.0 million.
Omics Tools and MDx Stocks Dip Slightly in March, Dragged Down by Several Genetics Firms
The GenomeWeb Top 40 was down 1 percent for the month of March while the Dow Jones, Nasdaq, and Nasdaq Biotechnology Index posted gains of 4 to 5 percent.
Sophia Genetics Q4 Revenues up 40 Percent on Bioinformatics Platform Sales
The company said that fourth quarter platform analysis volumes increased 50 percent year-over-year, helping drive revenue growth.
Sophia Genetics, Realm IDx Sign Letter of Intent to Expand NGS in Cancer Care
The firms expect to codevelop genomic applications based on Realm IDx subsidiary Ambry Genetics' TumorNEXT-HRD and other NGS assays.
Nov 10, 2021
Sophia Genetics Q3 Revenues Increase 44 Percent
Sep 30, 2021
OncoDNA, Sophia Genetics Partner on Tumor Profiling
Sep 10, 2021
Sep 9, 2021
Sophia Genetics Q2 Revenue Grows 72 Percent
Jul 21, 2021
Jul 19, 2021